Park Medi World Limited announced its revised earnings presentation for Q3 FY26 and nine-month period ended December 31, 2025, showcasing strong operational performance and continued execution of its growth strategy. The company delivered healthy revenue growth supported by stable patient volumes, improved case mix, and gradual ramp-up across newer and acquired hospitals. The company also hosted its maiden earnings call on January 29, 2026, marking the beginning of structured dialogue with the investor community.

Financial Performance Highlights

The company reported impressive financial results across key metrics for both quarterly and nine-month periods:

Revenue from operations reached ₹4,100 mn in Q3 FY26, representing a 17.76% increase from ₹3,481 mn in the corresponding quarter of the previous year. For the nine-month period, revenue grew 17.25% to ₹12,189 mn from ₹10,397 mn in 9M FY25. The company also reported a 24% growth in patient footfall to 6.6 lakh patients in the nine-month period from 5.32 lakh patients in the previous year.

Strategic Acquisitions Drive Expansion

Park Medi World strengthened its platform through two significant strategic acquisitions during the period. The company acquired a 100% stake in KP Institute of Medical Sciences (KPIMS) in an all-cash transaction of ₹245 crore. KPIMS is a 360-bed, NABH-accredited multi super-speciality hospital and among the largest in the Agra region, strengthening Park Group's presence in Uttar Pradesh under its cluster-based expansion strategy.

Additionally, the company acquired Febris Multi-Speciality Hospital in New Delhi through its wholly owned subsidiary Blue Heavens Health Care Pvt. Ltd. under the IBC process. This 200-bed multi-speciality hospital is strategically located in a densely populated catchment with access to Delhi, Haryana, and Western UP.

Operational Excellence and Capacity Expansion

The company demonstrated strong operational metrics with improved capacity utilization:

The company's bed capacity increased to 3,250 beds in 9M FY26 from 3,000 beds in the corresponding previous period. The occupancy ratio improved to 65% in 9M FY26 compared to 62% in 9M FY25, while Average Revenue per Operating Bed (ARPOB) rose to ₹27,406 from ₹25,527.

Aggressive Expansion Plans and Technology Adoption

During the earnings call, management outlined ambitious expansion plans to add 660 beds within FY26 itself. The Agra facility (360 beds) is scheduled to commence operations by February 15, 2026, while the Panchkula Greenfield project (300 beds) will start in the first week of March 2026. By FY28, the company plans to reach approximately 5,260 beds from the current 3,250 beds.

The company has invested heavily in advanced medical technology, including three fifth-generation da Vinci robots for robotic-assisted surgeries. Management reported conducting 25-30 kidney transplants per month and over 300 robotic joint replacements, contributing to improved product mix and higher ARPOB.

Financial Strength and Debt Reduction

Park Medi World significantly strengthened its balance sheet post-IPO. The company reduced its total term debt from ₹425 crore pre-IPO to approximately ₹15 crore as of January 31, 2026, with plans to become completely debt-free by February 2026. This positions the company well for funding its aggressive expansion plans.

Management Outlook and Strategic Focus

According to management commentary during the earnings call, the company remains focused on disciplined capital allocation, balance sheet strength, and measured expansion post-IPO. The company expects to maintain EBITDA margins in the 26%-27% range and PAT margins of 15%-17% over the medium to long term. Management also highlighted the recent CGHS rate hike of 12%-15%, which is expected to benefit the company from FY27, though they are conservatively accounting for a 7.5% impact.

Park Medi World maintains its position as the largest private hospital chain in Haryana with an extensive presence across North India, including Haryana, Delhi, Punjab, and Rajasthan. The company's cluster-based expansion approach enables brand recognition and resource sharing among hospitals located in proximity, supporting operational efficiencies and improved utilization over time.

Park Medi World Limited has announced the formal authorization of its Chief Financial Officer to handle regulatory disclosures and materiality determinations under SEBI regulations. The healthcare company has designated Mr. Rajesh Sharma, CFO, as the Key Managerial Personnel responsible for these critical compliance functions.

Regulatory Compliance Framework

The authorization comes in compliance with Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Under this framework, the Board of Directors has identified and authorized specific personnel to determine the materiality of events or information and make necessary disclosures to stock exchanges.

Key Personnel Authorization Details

The company has provided comprehensive contact information for the authorized personnel to ensure seamless communication with regulatory bodies and stakeholders:

Communication and Transparency

Park Medi World Limited has formally communicated this authorization to both major stock exchanges where its shares are listed. The company trades on BSE with scrip code 544645 and on NSE under the symbol PARKHOSPS. Additionally, the disclosure has been made available on the company's official website at parkhospital.in, ensuring transparency and easy access for all stakeholders.

Corporate Governance Enhancement

This formal authorization represents a structured approach to corporate governance and regulatory compliance. By designating specific Key Managerial Personnel for materiality determination and disclosure responsibilities, the company ensures streamlined decision-making processes and timely communication of material information to the market. The appointment strengthens the company's compliance framework and demonstrates its commitment to maintaining high standards of corporate governance.